Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trialMartin Wermke, Cedrik M. Britten, Peter Brossart et al.|Nature Medicine|2025Cited by 56
Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumorsMartin Wermke, Jason J. Luke, Winfried Alsdorf et al.|Molecular Cancer Therapeutics|2023Cited by 16
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trialMartin Wermke, Cedrik M. Britten, Dejka M. Araujo et al.|Nature Medicine|2025Cited by 5
687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patientsMartin Wermke, Cedrik M. Britten, Winfried Alsdorf et al.|Regular and Young Investigator Award Abstracts|2024Cited by 4
Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.Martin Wermke, Cedrik M. Britten, Winfried Alsdorf et al.|Journal of Clinical Oncology|2025Cited by 3